NCT03770273View on ClinicalTrials.gov

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Indolent Systemic Mastocytosis

Interventions

BIOLOGICAL

sarilumab

Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.

OTHER

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03770273 - Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | Biotech Hunter | Biotech Hunter